| Assay ID | Title | Year | Journal | Article |
|---|
| AID22935 | Elimination rate constant of the compound(400 mg/kg) administered orally in human | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID22779 | Elimination rate constant of the compound(25 mg/kg) administered intravenously in rat | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID14645 | The maximum plasma concentration (400 mg/kg) administered orally in human | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID20739 | The maximum time for retention (200 mg/kg) administered orally in human | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID20746 | The maximum time for retention (50 mg/kg) administered orally in rat | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID14639 | The maximum plasma concentration (15 mg/kg) administered intravenously in dog | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID20737 | The maximum time for retention (12.5 mg/kg) administered intravenously in monkey | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID14927 | The area under curve (400 mg/kg) administered orally in humans | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID20741 | The maximum time for retention (25 mg/kg) administered orally in marmoset | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID20736 | The maximum time for retention (12.5 mg/kg) administered intravenously in marmoset | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID160468 | Inhibitory activity against HIV-1 protease | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID14648 | The maximum plasma concentration (800 mg/kg) administered orally in human | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID20745 | The maximum time for retention (50 mg/kg) administered orally in fasted rat | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID14926 | The area under curve (30 mg/kg) administered orally in dog | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID14638 | The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID22777 | Elimination rate constant of the compound(15 mg/kg) administered intravenously in dog | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID20742 | The maximum time for retention (25 mg/kg) administered orally in monkey | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID20738 | The maximum time for retention (15 mg/kg) administered intravenously in dog | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID14919 | The area under curve (12.5 mg/kg) administered intravenously in marmoset | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID20747 | The maximum time for retention (800 mg/kg) administered orally in human | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID14920 | The area under curve (12.5 mg/kg) administered intravenously in monkey | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID20744 | The maximum time for retention (400 mg/kg) administered orally in human | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID14643 | The maximum plasma concentration (25 mg/kg) administered orally in monkey | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID22775 | Elimination rate constant of the compound(12.5 mg/kg) administered intravenously in marmoset | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID46358 | Concentration required to inhibit against HIV strain IIIB in CEM cell | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID22934 | Elimination rate constant of the compound(30 mg/kg) administered orally in dog | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID22937 | Elimination rate constant of the compound(800 mg/kg) administered orally in human | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID14922 | The area under curve (200 mg/kg) administered orally in humans | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID22774 | Elimination rate constant of the compound(100 mg/kg) administered orally in human | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID14644 | The maximum plasma concentration (30 mg/kg) administered orally in dog | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID18206 | Oral bioavailability (50 mg/kg) in fasted rat | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID20740 | The maximum time for retention (25 mg/kg) administered intravenously in rat | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID22936 | Elimination rate constant of the compound(50 mg/kg) administered orally in fasted rat | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID14928 | The area under curve (50 mg/kg) administered orally in fasted rat | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID14921 | The area under curve (15 mg/kg) administered intravenously in dog | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID14923 | The area under curve (25 mg/kg) administered intravenously in rat | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID14930 | The area under curve (800 mg/kg) administered orally in humans | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID14646 | The maximum plasma concentration (50 mg/kg) administered orally in fasted rat | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID18203 | Oral bioavailability (25 mg/kg) in monkey | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID14637 | The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID14640 | The maximum plasma concentration (200 mg/kg) administered orally in human | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID14647 | The maximum plasma concentration (50 mg/kg) administered orally in rat | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID14636 | The maximum plasma concentration (100 mg/kg) administered orally in human | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID22778 | Elimination rate constant of the compound(200 mg/kg) administered orally in human | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID18204 | Oral bioavailability (30 mg/kg) in dog | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID1891409 | Inhibition of SARS-CoV-2 main protease expressed in Escherichia coli using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 peptide as substrate at 100 uM incubated for 30 mins by FRET based assay relative to control | | | |
| AID22780 | Elimination rate constant of the compound(25 mg/kg) administered orally in marmoset | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID22776 | Elimination rate constant of the compound(12.5 mg/kg) administered intravenously in rmonkey | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID18207 | Oral bioavailability (50 mg/kg) in rat | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID14918 | The area under curve (100 mg/kg) administered orally in humans | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID14642 | The maximum plasma concentration (25 mg/kg) administered orally in marmoset | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID14641 | The maximum plasma concentration (25 mg/kg) administered intravenously in rat | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID20743 | The maximum time for retention (30 mg/kg) administered orally in dog | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID14924 | The area under curve (25 mg/kg) administered orally in marmoset | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID22781 | Elimination rate constant of the compound(25 mg/kg) administered orally in monkey | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID20735 | The maximum time for retention (100 mg/kg) administered orally in human | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID14929 | The area under curve (50 mg/kg) administered orally in rat | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID18202 | Oral bioavailability (25 mg/kg) in marmoset | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID14925 | The area under curve (25 mg/kg) administered orally in monkey | 1997 | Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1347151 | Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347405 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347057 | CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7
| Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347058 | CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7
| Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347410 | qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library | 2019 | Cellular signalling, 08, Volume: 60 | A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening. |
| AID1347059 | CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7
| Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |